NEW YORK and SYDNEY, June 23, 2015 /PRNewswire/ -- EnGeneIC Ltd, an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced today that the IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, has honored the Company with the Innovation Award in the Small Medium Enterprise (SME) Corporate (Medical/Biotech/Life Science/Science) category during the 2015 Thomson Reuters Australian Citation & Innovation Awards. EnGeneIC was one of 43 Australians and eight institutions acknowledged for leading scientific research and innovation in Australia.
EnGeneIC received the Innovation Award in recognition of the Company's proprietary EDV™ nanocell technology platform, which is a powerful nanoparticle drug, siRNA or miRNA delivery system designed to directly target and effectively kill tumor cells with minimal toxicity, while at the same time stimulate the immune system's natural anti-tumor response. Demonstrating the potential of EDV™ nanocells, a recent case study published in the peer-reviewed journal American Journal of Respiratory and Critical Care Medicine reported that a 51-year old male experienced a near complete response of his malignant pleural mesothelioma after participating in a clinical study testing the EDV™ technology.
EnGeneIC holds more than 160 patents worldwide governing its EDV™ platform. The patent portfolio does not rely on the licensing of any technology from a third party and has been developed entirely in house by the founders and Joint CEOs, Drs. Himanshu Brahmbhatt and Jennifer MacDiarmid.
Dr. MacDiarmid remarked, "This innovation award is a wonderful surprise, and we are very excited to be recognized by Thomson Reuters as a company that is poised to make a difference to cancer patients. The award is especially pleasing as it follows last week's news that dosing with the targeted EDV™ nanocell has enabled a near complete response in an end-stage mesothelioma patient."
The methodology used to determine the 2015 Thomson Reuters Australian Innovation Award recipients was developed by Thomson Reuters and is based on the methodology of the Thomson Reuters Top100 Global InnovatorsSM program. The research and analysis was performed using Thomson Reuters Derwent World Patents Index® (DWPISM), Thomson Innovation® and Thomson Data Analyzer®.
Criteria used to assess the level of innovation of candidate institutions and companies include:
- Size of patent portfolio: volume of Basic Inventions published over the most recent five years
- Success rate: ratio of published applications to granted patents over the most recent five years
- Extent of globalization: protecting an invention in major world markets indicates that the company places a significant value on those pieces of their intellectual property (IP); the Thomson Reuters Quadrilateral Patent Index™ was calculated to create a ratio to show which entities place a high value on their IP portfolios. The quadrilateral authorities comprise the Chinese Patent Office, European Patent Office, Japanese Patent Office and the United States Patent & Trademark Office
- Influence of the innovation: as determined by international citations to the invention, i.e. how often the invention is subsequently cited on other patent applications
"We are very pleased to have the opportunity to honor the individuals and institutions making significant contributions in Research & Innovation," said Jeroen Prinsen, senior director for Australia and New Zealand, Thomson Reuters. "Australia plays an important role in the global scholarly and commercial ecosystem, and it is through the use of Thomson Reuters data that we are able to qualify and quantify this contribution, and give credit where credit is due. Innovation is a key driver of today's global economy. These institutions understand the value of protecting their intellectual assets and bringing them to market for commercial advantage."
About EDV™ Nanocell Technology
EnGeneIC's bacterially-derived EDV™ nanocells are a powerful nanoparticle drug or siRNA or miRNA delivery system designed to directly target and effectively kill tumor cells with minimal toxicity, while at the same time stimulate the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver intracellularly a drug or siRNA or miRNA payload. In parallel, the bacterial cell wall of the nanocells stimulates key components of the immune system, which are then activated to seek out and destroy cancer cells.
About EnGeneIC, Ltd.
EnGeneIC is an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutic and other therapeutic molecules. The company's lead technology platform, EDV™ utilizes antibody-targeted, bacterially derived, non-living "nanocells" to release high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into targeted tumor cells. In doing so, EDVTM nanocells enable current cancer treatments to be more potent and far less toxic, while also offering a potential new means for treating drug-resistant cancers. EnGeneIC is currently planning to undertake clinical trials in several cancer indications in Australia and USA.
For more information please visit www.engeneic.com
Himanshu Brahmbhatt, Ph.D.
Joint-CEO and Director
Australia Media Contact:
SOURCE EnGeneIC, Ltd.